Influential analysis has concluded that "breakthrough" Alzheimer’s drugs are unlikely to benefit patients.
Researchers said the impact was "well below" what was needed to make a difference to dementia patients’ lives.
However, their report has also provoked a vicious backlash from equally esteemed scientists who label it as fundamentally flawed.
Subscribe to our channel here: https://bbc.in/bbcnews
For the latest news download the BBC News app or visit BBC.com/news
#BBCNews
